2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle C
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Biological Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Animal Model
PAPER

1040 FOLR2 directed CAR T cells target immunosuppressive plasmacytoma-associated FOLR2+ macrophages and prolong survival in a murine model of relapsed/refractory multiple myeloma

Qi Yan, PhD, Joshua Rivera2, Caleb Karl Stein, PhD3, Jalal Rostampour4, Saeed Daneshmandi, PhD5, Jianmin Wang6, Ahmed Belal7, Ronald Alberico8, Ian Lund, PA-C9, Kristina Slemmer10, Sarah Parker11, Hamza Hassan, MD12, Erin Meermeier, PhD13, YuanXiao Zhu14, Kirsten Pfeffer, PhD15, Megan T. Du, MS16, Meaghen E. Sharik17, Jonathan Keats, PhD18, Nicholas Banovich, PhD19, Nikhil Munshi, MD20, Taxiarchis Kourelis, MD21, AJ Robert McGray22, Philip L. McCarthy, MD23, P. Leif Bergsagel, MD24, Jens Hillengass, MD, PhD25, Mehmet Kemal Samur, PhD26, Marta Chesi, PhD27, Hemn Mohammadpour, DVM, PhD28
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
3 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
13 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
14 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
15 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
16 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
17 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
18 Tgen Translational Genomic Institute, Phenix, Arizona, United States
19 Tgen Translational Genomic Institute, Phenix, Arizona, United States
20 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
21 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Rochester, MN, Rochester, Minnesota, United States
22 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
23 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
24 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
25 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
26 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
27 Department of Medicine, Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, Scottsdale, Arizona, United States
28 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Introduction

Multiple myeloma (MM) remains mostly incurable, and the majority of patients develop relapsed/refractory disease (RRMM) despite therapy. The myeloid tumor microenvironment (TME) contributes to MM progression, yet how macrophages drive relapse following treatment remains unclear. Here we identify a distinct C1Q+FOLR2+ macrophage population (FRβ+ MF) that is enriched among myeloma cells in plasmacytomas (PCTs; all plasma cell tumor masses including intramedullary osteolytic lesions (OL), intramedullary focal lesions and extramedullary sites of disease) from RRMM, is associated with disease progression, and is selectively targetable by FOLR2 directed CAR T cells.

Methods

High-resolution single-cell RNA sequencing (scRNA-seq) was performed on freshly isolated myeloid cells (CD11b+ CD3- CD56- CD138-) from bone marrow (BM) and PCTs of patients with newly diagnosed MM (NDMM) and RRMM, healthy donor BM, and immunocompetent murine MM models. FRβ+ MF localization and phenotype were assessed by multicolor immunofluorescence (mIF, Vectra Polaris) and flow cytometry, and T cell suppression assay on sorted human CD68+FOLR2+ macrophages. FOLR2 targeting CAR T cells were generated and tested against FOLR2+ RAW264.7 macrophages in vitro and its specificity was confirmed by co-culture with murine F4/80+ macrophages containing both FOLR2+ and FOLR2− cells. In vivo efficacy was evaluated in a Vk*MYC-derived RRMM model (Vk12653). Mice were inoculated with MM cells, irradiated, and followed to relapse. Relapsed mice were then administered FOLR2 targeted CAR T cells or non-transduced T cells, with monitoring of overall survival (OS) and monoclonal protein (M-spike).

Results

scRNA-seq identified a distinct FRβ+ MF population that was markedly enriched in RRMM, particularly in PCT, and minimally detected in healthy-donor BM. By mIF, FRβ+ MF preferentially localized among myeloma cells, whereas other myeloid populations resided at the tumor periphery. Ex vivo T cell suppression assay and secretome analysis demonstrated their potent immunosuppressive activity. Consistent with their potential role in disease persistence, clinical scRNA-seq and bulk Affymetrix analyses showed that persistence of FRβ+ MF following therapeutic interventions, including autologous hematopoietic stem cell transplantation (auto-HCT), was associated with inferior clinical outcomes. Notably, 7 out of 8 patients with a high percentage of FRβ+ MFs at 100 days post-auto-HCT had progression of disease (PD) within two years, whereas 9 of 14 patients with fewer FRβ+ MFs had no PD by seven years. In vitro, FOLR2 targeting CAR T cells efficiently and specifically eliminated FRβ+ MF. To confirm the CAR T cell specificity, CAR T cells were co-cultured with a mixture of F4/80+FOLR2+ and F4/80+FOLR2− murine populations. FOLR2 targeting CAR T cells selectively depleted F4/80+FOLR2+ macrophages while preserving F4/80+FOLR2− macrophages. In vivo, treatment with FOLR2 targeted CAR T cells in the RRMM murine model prolonged OS (P <0.01) compared with non-transduced T cell controls and untreated controls. Tumor progression was significantly delayed by CAR T treatment compared to control groups.

Conclusion

We provide comprehensive phenotypic and functional characterization of an immunosuppressive FRβ+ MF population that resides among myeloma cells and whose persistence predicts post-treatment relapse, supporting its utility as a biomarker of relapse risk. FOLR2 targeting CAR T cells selectively target these cells and prolong survival in an RRMM model, establishing proof of concept for immune cell directed CAR T therapy against the myeloid TME and a translatable strategy for MM.

Qi Yan, PhD: No relevant conflicts of interest to declare.